HOUSTON, TX - August 4, 2025 (NEWMEDIAWIRE) - Neutra Corp (OTC: NTRR) is hitting its stride with the purposeful growth in the clinical research industry with Neutra Life Sciences. Since the successful launch of its Site Management Organization (SMO), Neutra Life Sciences has strategically positioned itself for significant growth in the latter part of 2025 and the beginning of 2026. Neutra Life Sciences has solidified its multi-specialty platform by securing another suite of Joint Venture Partnerships.
These new joint venture sites will be in the onboarding process:
- Podiatry
- Epic Foot & Ankle Centers (www.epicfootandankle.com)
- Radiation Oncology
- Aspire Hospital Cancer Centers (www.aspirehealthcorp.com)
- Dermatology
- Radiant Dermatology & Aesthetics Clinic (www.radiantdermtx.com)
Expanding into more specialties gives Neutra Life Sciences a significant advantage over other organizations in the space. This diversification in medical specialties allows NLS to serve a broader patient population and meet increasing demands in clinical research.
Looking ahead, Neutra Life Sciences plans to continue expanding into additional specialties, further enhancing its ability to support Contract Research Organizations (CROs) and Sponsors with a wider array of clinical indications. This strategic growth enables the company to play a critical role in accelerating the development of innovative treatments across a broader spectrum of therapeutic areas.
“Our growth reflects the increasing demand for high-quality, integrated clinical research solutions,” said Sydney Jim, President and CEO of Neutra Corp. “By aligning with established private practices and opening these new specialized sites, we are not only expanding our service offerings but also fostering innovation in patient care and research.”
Neutra Life Sciences remains focused on building a robust network of clinical research sites, delivering exceptional services to its partners, and advancing its mission to improve health outcomes through cutting-edge collaboration.
For more information about the role of clinical research sites in advancing medicine, or to learn how to participate in a clinical trial, please contact Neutra Life Sciences via phone 281-598-0200 or email at info@neutralifesciences.com.
Neutra has made the strategic decision to wind down its subsidiary in the Hemp-Based Cannabis entity, VIVIS Corporation, as part of a broader shift toward long-term growth in the life sciences sector. This transition reflects the company's renewed focus on advancing its clinical research capabilities through its newly launched site management organization (SMO). By reallocating resources and leadership attention to the SMO business, Neutra aims to support high-quality clinical trials and expand its presence in the evolving healthcare and biotechnology landscape. This move underscores the company’s commitment to innovation and delivering value in areas with greater regulatory stability and long-term market potential.
About Neutra Corp
Neutra Corp is a health and wellness company dedicated to advancing life sciences, clinical research, and innovative consumer health solutions. With a diversified portfolio, Neutra Corp focuses on life sciences technology, clinical research, and high-quality wellness products designed to support overall health and well-being.
Committed to empowering individuals with the tools and knowledge needed to make informed healthcare decisions, Neutra Corp integrates cutting-edge research with real-world applications. Its expansion into life sciences and clinical research reinforces its mission to drive innovation in healthcare, while its wellness product line provides natural solutions for consumers seeking alternative wellness options.
Through strategic acquisitions and partnerships, Neutra Corp continues to grow its impact in the life sciences and health sectors, bridging the gap between research, technology, and consumer wellness. For investing, information and performance data, please visit https://www.neutrainc.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, a description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
View the original release on www.newmediawire.com
